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Background: Breast cancer circulating biomarkers include carcinoembryonic antigen and carbohydrate antigen
15–3, which are used for patient follow-up. Since sensitivity and specificity are low, novel and more useful
biomarkers are needed. The presence of stable circulating microRNAs (miRNAs) in serum or plasma suggested a
promising role for these tiny RNAs as cancer biomarkers. To acquire an absolute concentration of circulating
miRNAs and reduce the impact of preanalytical and analytical variables, we used the droplet digital PCR (ddPCR)
technique.
Results: We investigated a panel of five miRNAs in the sera of two independent cohorts of breast cancer patients
and disease-free controls. The study showed that miR-148b-3p and miR-652-3p levels were significantly lower in the
serum of breast cancer patients than that in controls in both cohorts. For these two miRNAs, the stratification of
breast cancer patients versus controls was confirmed by receiver operating characteristic curve analyses. In
addition, we showed that higher levels of serum miR-10b-5p were associated with clinicobiological markers of poor
prognosis.
Conclusions: The study revealed the usefulness of the ddPCR approach for the quantification of circulating
miRNAs. The use of the ddPCR quantitative approach revealed very good agreement between two independent
cohorts in terms of comparable absolute miRNA concentrations and consistent trends of dysregulation in breast
cancer patients versus controls. Overall, this study supports the use of the quantitative ddPCR approach for
monitoring the absolute levels of diagnostic and prognostic tumor-specific circulating miRNAs.
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Breast cancer is the most frequent cancer and the sec-
ond leading cause of cancer death among women in in-
dustrialized countries. Approximately 1.3 million women
develop breast cancer every year [1]. Advances in early
diagnosis and treatments have contributed to the de-
crease of mortality rates over the years. The overall 5-
year survival is 90 % when breast cancer is diagnosed at* Correspondence: ngm@unife.it
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creativecommons.org/publicdomain/zero/1.0/an early stage as opposed to 20 % if disease has spread
to distant organs [2]. Physical examination, mammog-
raphy, and biopsy are the current approaches to breast
cancer diagnosis [3]. Carcinoembryonic antigen and
carbohydrate antigen 15–3 are circulating tumor
markers that are mainly used for patient follow-up [4].
However, the sensitivity of these markers is low, thus
calling attention to the need for novel and more accurate
noninvasive diagnostic biomarkers.
Studies on circulating microRNAs (miRNAs) opened
potential opportunities for the discovery of new tumor
biomarkers. miRNAs are a class of small noncoding
RNAs that regulate gene expression at the post-s article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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regulation of most, if not all, human genes and their in-
volvement in the deregulation of pathological states such
as cancer has been well established [6]. Moreover, miRNAs
can be detected in serum or plasma, and their levels may
be specifically altered in pathological conditions. BecauseTable 1 Clinicopathological features of breast cancer patients
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acM Clinical evidence of metastasis
HER2/neu human epidermal growth factor receptor 2, ER Estrogen receptor, PR Progof their remarkable stability in plasma and serum and the
possibility of measuring their levels using noninvasive
methods, various studies have suggested a role for circulat-
ing miRNAs as novel cancer biomarkers [7–11].
Despite promising results, however, it became evident
that several variables (sample collection and storage, RNACohort A (n = 28) Cohort B (n = 59)
65.3 (±14.4) 56.7 (±10.4)
33–91 34–81
3 (11 %) 14 (24 %)
7 (25 %) 1 (2 %)
18 (64 %) 44 (75 %)
21 (75 %) 48 (81 %)
4 (14 %) 4 (7 %)
1 (4 %) 1 (2 %)
2 (7 %) 6 (10 %)
21 (75 %) 28 (47 %)
7 (25 %) 27 (46 %)
0 4 (7 %)
21 (75 %) 35 (59 %)
6 (21 %) 16 (27 %)
0 6 (10 %)
1 (4 %) 1 (2 %)
0 1 (2 %)
28 (100 %) 57 (97 %)
0 2 (3 %)
16 (57 %) 24 (41 %)
11 (39 %) 24 (41 %)
1 (4 %) 9 (15 %)
0 2 (3 %)
5 (18 %) 11 (19 %)
18 (64 %) 14 (24 %)
5 (18 %) 34 (58 %)
26 (93 %) 41 (69 %)
2 (7 %) 16 (27 %)
0 2 (3 %)
19 (68 %) 35 (59 %)
9 (21 %) 22 (37 %)
0 2 (3 %)
3 (11 %) 11 (19 %)
25 (89 %) 44 (75 %)
0 1 (2 %)
0 3 (5 %)
1 (4 %) 9 (15 %)
esterone receptor
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methods) could affect final results [12]. In this study,
we took advantage of the droplet digital PCR (ddPCR)
technique for assessing circulating miRNA levels, an
approach that allows absolute quantification without
the need for internal/external normalization. Using
ddPCR, we investigated five miRNAs in the sera of
two independent cohorts of breast cancer patients and
disease-free controls to verify whether miRNAs couldFig. 1 Levels of miRNAs in sera of two independent cohorts of breast cancer
ddPCR technique and expressed in copies per microliter in each sample. Each
cohorts. miR-652-3p and miR-148b-3p exhibited a statistically significant reduc
Welch’s correction was performed to assess significance of differences betwee
be significant. BRCA breast cancer patientsrepresent useful diagnostic biomarkers of breast
cancer.
Results
Circulating miRNAs in sera of breast cancer patients
versus healthy controls
We selected five miRNAs (miR-10b-5p, miR-145-5p,
miR-148b-3p, miR-425-5p, miR-652-3p) derived from
microarray experiments [13] or described in recentlyand disease-free patients. The level of each miRNA was measured by the
miRNA displays comparable levels and consistent dysregulation in both
tion in breast cancer patients in both cohorts. The unpaired t-test with
n patient and control groups. P-values of less than 0.05 were deemed to
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ing biomarkers (Additional file 1: Table S1). Two inde-
pendent sets of serum samples from breast cancer
patients and disease-free controls were analyzed
(Table 1). One group of samples was collected at the
University Hospital of Ferrara, Italy, from 2012 to 2014
(cohort A), while the second group of samples was col-
lected at the Mercy’s Woman Center in Oklahoma City,
OK, USA, from 2005 to 2013 (cohort B). Serum samples
from both cohorts were collected and processed accord-
ing to the same protocol, and the levels of circulating
miRNAs were assessed by ddPCR. This technique allows
the measurement of the absolute concentration of circu-
lating miRNAs with no need for a reference gene, a con-
dition particularly important for this type of sample.
Hence, miRNA levels were expressed as copies per
microliter of serum.
miR-148b-3p and miR-652-3p levels were significantly
lower in breast cancer patients than in controls in bothFig. 2 Diagnostic potential of miR-148b and miR-652. Receiver operating c
exhibit a significant ability to predict breast cancer in both cohorts. Binary
generated to evaluate the ability of chosen miRNAs to distinguish cancer pcohorts (p = 0.0042 and p < 0.0001, respectively, in co-
hort A; p = 0.0115 and p = 0.0043, respectively, in cohort
B) (Fig. 1). miR-145-5p and miR-425-5p were also
down-regulated in breast cancer patients compared with
controls in both cohorts, but the differences were statis-
tically significant in cohort B only (miR-145-5p: p =
0.0257, miR-425-5p: p = 0.0226) (Fig. 1). Conversely, miR-
10b-5p exhibited a weak increase in cancer patients com-
pared with controls. This trend was statistically significant
in cohort B only (p = 0.016) (Fig. 1). The reduced represen-
tation of high tumor stages was likely responsible for the
lack of statistical significance for the results of cohort A
(see next section). When combined, the two cohorts pro-
duced a highly significant discrimination between cancer
patients and controls for all investigated miRNAs, with the
strongest discrimination achieved by miR-652 and miR-
148b (Additional file 1: Figure S1). To validate these results
in comparison with the most commonly used method
based on Real Time PCR (RT-PCR) approach, weharacteristic (ROC) curve analyses show that miR-148b and miR-652
logistic regression analysis was performed and ROC curves were
atients from controls. AUC area under the curve, CI confidence interval
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we employed the non-human Cel-miR-39, which we rou-
tinely add at a defined concentration to any serum sample.
Results of these analyses confirmed the significant discrim-
ination between samples from breast cancer patients versus
controls in the same direction shown by ddPCR-based ana-
lyses, thus showing that ddPCR did not introduce any ex-
perimental bias if compared to quantitative RT-PCR
(Additional file 1: Figure S2).
Receiver operating characteristic (ROC) curve analysis
was performed to evaluate the diagnostic value of the
five miRNAs (Fig. 2). miR-652 and miR-148b appeared
to represent valuable diagnostic biomarkers. miR-652
was of particular interest because of the highly signifi-
cant ROC curves in both cohorts. Here, we confirmed a
significant lower level of miR-652-3p not only in Lu-
minal A cancer patients (estrogen receptor [ER]/proges-
terone receptor [PR] positive and human epidermal
growth factor receptor 2 [HER2] negative), as previously
reported [14]], but also in non-Luminal A cancer pa-
tients, versus controls (p = 0.020 for Luminal A and p =
0.004 for non-Luminal A) (Additional file 1: Figure S3).
Association of miR-10b with prognostic parameters
Associations between each miRNA and clinicopathologi-
cal features were investigated in patients of cohort B
(Table 2). Since cohort A included only patients withTable 2 miR-10b-5p: copies per microliter of serum according to cli
Feature
Tumor size (pT) pT1
pT2
pT3















ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growtstage I or II tumors, it was excluded from these analyses.
In cohort B, the level of serum miR-10b-5p revealed a
concordant increase with tumor stage (Fig. 3). Patients
with stage II to IV cancers exhibited significantly higher
levels of miR-10b in comparison with patients with a
stage I tumor (p = 0.0047) or with controls (p = 0.0028).
Conversely, no significant difference was found between
stage I patients and controls.
Notably, miR-10b-5p was also significantly up-
regulated in association with other clinicopathological
features of prognostic significance, including higher
tumor grading and lymph node metastases (Fig. 3). Al-
beit not statistically significant, the average level of miR-
10b-5p was also higher in patients carrying HER2-
positive or ER/PR-negative cancers. The number of
triple negative breast cancer were too few to lead to any
meaningful result.
These data indicate that miR-10b-5p is significantly as-
sociated with parameters associated with a poor progno-
sis. No significant association was found between miR-
145-5p, miR-148b-3p, miR-425-5p, or miR-652-3p and
any clinicopathological feature.
Discussion
The presence of stable miRNAs circulating in plasma or
serum suggested their potential use as noninvasive bio-
markers in cancer patients. In the last few years, severalnicopathological features
Cohort A (Italy) Cohort B (USA)
Average copies/μL ± SD Average copies/μL ± SD
(n = number of patients) (n = number of patients)
108.7 ± 78.0 (n = 19) 98.6 ± 47.3 (n = 28)
97.3 ± 55.9 (n = 6) 143.4 ± 70.3 (n = 27)
/ 75.0 ± 11.9 (n = 4)
88.7 ± 37.2 (n = 18) 101.2 ± 54.6 (n = 35)
113.3 ± 89.4 (n = 7) 145.2 ± 70.8 (n = 23)
82.9 ± 28.5 (n = 14) 91.3 ± 45.9 (n = 23)
107.7 ± 79.9 (n = 10) 128.0 ± 61.8 (n = 25)
134.0 (n = 1) 130.5 ± 60.2 (n = 8)
/ 242.2 ± 110.3 (n = 2)
80.8 ± 36.5 (n = 5) 114.9 ± 43.2 (n = 11)
112.7 ± 88.6 (n = 18) 91.2 ± 58.8 (n = 13)
105.0 ± 54.3 (n = 5) 136.0 ± 74.81 (n = 34)
142.1 ± 98.44 (n = 17) 115.0 ± 60.1 (n = 35)
74.0 (n = 1) 131.9 ± 89.4 (n = 16)
103.7 ± 80.8 (n = 3) 112.9 ± 65.5 (n = 11)
115.8 ± 88.4 (n = 25) 145.8 ± 75.0 (n = 44)
74.0 (n = 1) 117.8 ± 90.2 (n = 9)
118.2 ± 85.61 (n = 27) 121.5 ± 63.36 (n = 49)
h factor receptor 2
Fig. 3 Serum miR-10b-5p increases in patients presenting poor prognostic parameters. a Levels of miR-10b increased progressively according to
tumor stage. Levels from patients with stages II-IV cancer exhibit a significant difference in comparison to those from patients with stage I cancer
(p = 0.0047) or controls (p = 0.0028). The diagnostic value of miR-10b was assessed by receiver operating characteristic curve analysis. No significant
difference was found between stage I and controls. BRCA breast cancer patients, AUC area under the curve. b Higher levels of miR-10b were associated
with various clinicopathological parameters: lymph node metastasis (pN) (p = 0.014) and tumor grade (p = 0.026). Albeit not statistically
significant, a trend toward increased levels of miR-10b was also detected in cases characterized by increased tumor size (pT) or as being
human epidermal growth factor receptor 2 positive (HER2+) or estrogen receptor/progesterone receptor negative (ER-/PR-). “PRE” or “POST”
refer to the menopausal status
Mangolini et al. Biomarker Research  (2015) 3:12 Page 6 of 9authors have demonstrated that a number of circulating
miRNAs could discriminate breast cancer patients from
healthy individuals [15, 16] or could be linked to breast
cancer subtypes [14, 17]. Unfortunately, the combined
effects of several variables made results poorly reprodu-
cible and their translation into clinically useful applica-
tions not feasible [12, 18–20]. For example, the
heterogeneity of investigated populations (age, tumor
features), or the differences in sample type (plasma or
serum) or sample processing protocols could have been
responsible for the apparent discrepancies among the
various studies. Moreover, a variety of methods were
used to normalize data, thereby producing non-
comparable or difficult-to-compare results [12].
Here, we used the ddPCR technique to measure circu-
lating miRNAs. ddPCR is a technique that can achieveabsolute quantification of nucleic acids by combining
limiting dilutions, end-point PCR, and Poisson statistics.
In fact, the partitioning of the PCR reaction into up to
20,000 separate droplets mimics a binary distribution of
the target. More important, being an end-point PCR,
ddPCR can tolerate wide variations in amplification effi-
ciencies without affecting copy number estimation of the
target [21–24].
Using ddPCR, we analyzed the levels of five miRNAs
in the serum of two independent cohorts of breast can-
cer patients and disease-free controls. Blood samples
were collected at two independent institutions and proc-
essed separately, with no differences in procedures for
obtaining serum samples. We analyzed serum, instead of
plasma, as it is the most commonly available patient ma-
terial, and the procedure used to collect serum is
Mangolini et al. Biomarker Research  (2015) 3:12 Page 7 of 9homogeneous at different institutions, thus helping to
reduce uncertainties in preanalytical procedures. Not-
ably, all of the analyzed miRNAs showed comparable ab-
solute levels in the sera of the two cohorts (see Fig. 1).
Most important, both cohorts exhibited consistent
trends of dysregulation in breast cancer patients versus
controls. The differences between breast cancer cases
and controls in cohort B were statistically significant for
all five miRNAs, whereas only miR-148b-3p and miR-
652-3p reached statistical significance in cohort A,
possibly because of differences in clinicopathological
characteristics. We performed ROC curve analyses in
which we evaluated the possible diagnostic potential of
the five circulating miRNAs. Areas under the curves and
P-values were significant for miR-148b-3p and miR-652-
3p in both cohorts (see Fig. 2), suggesting the potential
value of these two miRNAs as breast cancer biomarkers.
Our data on circulating miRNAs show both similarities
to and discrepancies from those of previous reports (listed
in Additional file 1: Table S1). However, differences in ex-
perimental settings and technical approaches make it diffi-
cult to compare the findings from various reports. Similar
to our findings, three previous reports found a decreased
level of miR-145-5p in breast cancer patients [17, 25, 26].
The up-regulation of miR-10b-5p in breast cancer patients
in our study is also in agreement with several published re-
ports [16, 25, 27]. We did not find significant differences in
cohort A. However, since this group consisted of patients
carrying stage I or II cancers, this finding does not contra-
dict a positive correlation between miR-10b and more ad-
vanced disease; it is also consistent with the results
described in a report by Roth et al., who found a higher
level of miR-10b in patients with metastatic disease [10].
For mir-652-3p, our results are in agreement with one re-
port that indicated a decreased level in patients with Lu-
minal A-like breast cancer in comparison with controls
[14]. Conversely, Cuk et al. showed increased levels of miR-
652-3p, likely because the study was performed on plasma
instead of serum samples [15]. In support of this sugges-
tion, analysis of a small number (n = 20) of plasma samples
from our breast cancer cohort revealed that miR-652-3p
was indeed increased in breast cancer patients compared
with that in controls (data not shown). Finding an opposite
trend in serum or plasma samples is not new [12, 13] and
raises the question about the different genesis of circulating
miRNAs [28]. Concerning miR-148b-3p and miR-425-5p,
the published literature reports opposite results to ours, as
both miRNAs were found to be higher in breast cancer pa-
tients than in healthy controls. However, studies on miR-
148b were all performed by using plasma [15, 29, 30],
whereas the miR-425 study was performed with serum,
but normalization was based on the mean of assays per-
formed on all samples [17]; thus, these results are not dir-
ectly comparable with ours.In the search for possible correlations with clinico-
pathological features, we found that miR-10b-5p levels
were increased in the serum of patients with a high can-
cer stage or grade, or with the presence of lymph node
metastases. Albeit not statistically significant, the average
expression of miR-10b-5p was also higher in cases with
ER/PR-negative tumors and in cases with HER2-positive
tumors. Together, these findings indicate that miR-10b-
5p represents a biomarker of tumor aggressiveness. This
suggestion is also supported by other studies that indi-
cated higher levels of circulating miR-10b in patients
with metastatic breast cancer and worsening clinical
stage [10, 27, 31]. It is notable that the role of miR-10b
in invasion and metastasis has been thoroughly investi-
gated and its importance proven [32–35]. miR-10b has
also been found to be highly expressed in the vascula-
ture of high-grade breast cancer [36]. Taken together,
these findings suggest that tumor and microenvironment
features may be directly responsible for the increased
levels of circulating miR-10b in the bloodstream of pa-
tients with advanced breast cancer. The possibility of
assessing the absolute levels of miR-10b in the serum of
patients by using a robust technique such as ddPCR
could represent a potential new approach for monitoring
disease behavior in breast cancer patients.
Conclusions
Overall, this study supports the use of the quantitative
ddPCR approach for monitoring the absolute levels of
specific miRNAs as diagnostic and prognostic serum
biomarkers in breast cancer patients.
Methods
Study cohorts
Two cohorts of patients were investigated. Serum sam-
ples from cohort A (n = 55) were collected at the Gen-
eral Surgery Unit of the University Hospital of Ferrara,
Italy, from 28 breast cancer patients and 27 age-
matched disease-free controls. Serum samples from
cohort B (n = 94) were collected at the Mercy Women’s
Center in Oklahoma City, OK, USA, from 59 breast
cancer patients and 35 age-matched controls (Add-
itional file 1: Table S2). Ethical approval was granted
by the ethics committees of the respective institutions.
Written informed consent was obtained from all indi-
viduals enrolled in the study. Table 1 summarizes the
clinicopathological features of the patients.
Sample preparation and RNA purification from serum
Blood samples from cohort A and B were collected in red
stopper clot tubes (Greiner Bio-One VACUETTE in co-
hort A, BD Vacutainer in cohort B) and processed within
1 h; they were centrifuged at 1000 g for 10 min at room
temperature, and serum was stored at −80 °C in 200 μL
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miRNA cel-miR-39-3p (ucaccggguguaaaucagcuug) from
C.Elegans (synthesized by IDT) was added to each aliquot.
Total RNA was isolated from 200 μL of serum by using
the MiRNeasy kit (Qiagen). RNA was eluted from spin
columns in 35 μL of nuclease-free water.
Reverse transcription, ddPCR and Real-Time PCR
cDNA was synthesized in a 20 μL reaction by using the
Universal cDNA synthesis kit II (Exiqon), starting from
3 μL of RNA according to the manufacturer’s guide-
lines for serum and plasma samples. Synthesized cDNA
was diluted 50-fold, and 8 μL was assayed in a 20 μL
PCR reaction volume according to the manufacturer’s
protocol for miRCURY LNA Universal RT microRNA
PCR (Exiqon) with EvaGreen (Bio-Rad). Each PCR re-
action was mixed with 70 μL of droplet generator oil
for EvaGreen in a disposable cartridge and applied to
the QX200 droplet generator device (Bio-Rad) that por-
tioned each sample into 20,000 nanoliter-sized drop-
lets. Each sample was then transferred into a 96-well
PCR plate and PCR was performed to the end point ac-
cording to the manufacturer’s protocol (Bio-Rad). The
same procedure was applied to all test samples and nega-
tive controls. At the end of the PCR reaction, the QX200
droplet reader (Bio-Rad) was used to count PCR-positive
and PCR-negative droplets: the “singulator” unpacks the
emulsified droplets and streams them in a single line past
a two-color optical detection system. Positive droplets,
which contain at least one copy of the target miRNA, ex-
hibit increased fluorescence compared with negative drop-
lets. The fraction of PCR-positive droplets enables the
target to be quantified according to Poisson distribution.
Quantitative Real-Time PCR was performed on miR-10b-
5p and miR-652-3p using the ExiLent CyberGreen master-
mix (Exiqon). Cel-miR-39 was used to normalize miRNAs
levels with the 2^-ΔΔCt method.
Statistical analysis
Statistical analysis was performed by using Prism software
version 5.0 (GraphPad, La Jolla, CA). An unpaired t-test
with Welch’s correction was performed to assess the sig-
nificance of differences between data distribution. A p-
value of less than 0.05 was deemed to be significant. Bin-
ary logistic regression analysis was performed and ROC
curves were generated to evaluate the ability of the chosen
miRNAs to discriminate cancer cases versus controls.
Additional file
Additional file 1: Figure S1. Distribution of miRNA levels in sera of the
two combined cohorts of breast cancer and disease-free patients. Figure
S2. Validation of ddPCR results using Real-Time PCR. Figure S3. Serum
miR-652-3p is significantly reduced in patients affected by either LuminalA or non-Luminal A breast cancers. Table S1. Published data on circulating
microRNAs in human breast cancer patients. Table S2. Demographic
characteristics of study populations.
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